Approved comparison material connected to this topic.
5 total recordsSource comparisons are presented without a generated winner.
NEJM 2010 (pooled) 806 HIV+ with lipohypertrophy 26 weeks 15.2% −0.8% Established selective VAT reduction without corresponding SAT loss in HIV population Diabetes Care 2024 218 metabolic syndrome 17.4% −1.2% …
Tesamorelin GHRH receptor agonist. Stimulates pulsatile endogenous GH secretion High. Targets visceral adipocytes via elevated GH receptor density 15.2% median reduction (Lancet 2010 trial) 26–38 minutes (GH e…
Before comparing interventions, context matters: visceral fat responds poorly to generalised weight loss strategies. Subcutaneous fat mobilises first during caloric deficit, and VAT reduction typically lags by…
How does tesamorelin compare to other VAT-reduction strategies in 2026? This table breaks down mechanism, timeline, selectivity, and clinical evidence. Tesamorelin 2mg/day GHRH receptor agonist → pulsatile GH …
Tesamorelin 2mg daily GHRH analogue. Restores pulsatile GH secretion 15–18% (NEJM trials) Minimal (<2%) IGF-1 ↑, glucose tolerance unchanged, triglycerides ↓ 15–20% Most selective VAT reduction of any pharmaco…